This multi-marker strategy, incorporating Gal-3, allows clinicians to more accurately pinpoint patients at the highest absolute risk who would derive the greatest benefit from intensive monitoring, early aggressive HF pharmacotherapy (e.g., sacubitril/valsartan, SGLT2 inhibitors), and close follow-up to prevent remodeling and HF progression. This evidence concerns the gene LGALS3 and hydrops fetalis.